Terremoto Biosciences

Investment area

Venture Investments


North America

Date of investment

November 2023

Terremoto Biosciences is a drug discovery and development company creating highly targeted, small molecule medicines with unmatched selectivity, potency and efficacy designed to deliver superior therapeutic benefit to patients. Terremoto is supported by leading investors including OrbiMed, Third Rock Ventures, EcoR1 Capital, Novo Holdings and Cormorant Capital.

Visit site


Daniel O’Connell


Departments: Venture Investments, Novo Ventures US Inc.

Daniel O’Connell joined Venture Investments in 2022 as Partner based in the San Francisco office.

Prior to joining Venture Investments, Daniel was Executive Director, Equity and Venture Capital/Corporate Development at BMS, where he was responsible for managing direct equity investments and LP positions in venture funds as well as leading the evaluation and acquisition of public companies across all areas of interest to BMS. Before BMS, Daniel was an Investment Director with Arix Bioscience and a Senior Associate with Orbimed. Daniel was also Associate Director, Cardiovascular Research at Arisaph Pharmaceuticals.

Daniel completed his undergraduate degree in Chemistry and Mathematics at MIT, and his MD and PhD from Tufts University.